Form 4: Bio-Techne Corp Executive Shane Bohnen Reports Stock Transactions

Shane Bohnen, SVP General Counsel of Bio-Techne Corp, reports the acquisition and disposal of common stock and restricted stock units on April 3, 2024.

Summary

• On April 3, 2024, Shane Bohnen, SVP General Counsel of Bio-Techne Corp, engaged in transactions involving the company's stock.
• Bohnen acquired 2,259 shares of common stock through the vesting of restricted stock units.
• Concurrently, Bohnen disposed of 2,394 shares of common stock.
• Additionally, 747 shares were disposed of at a price of $67.87.
• Following these transactions, Bohnen directly owns 1,647 shares of common stock.
• Bohnen also holds 4,519 restricted stock units.

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing detailing stock transactions. It doesn't inherently convey positive or negative sentiment about the company's performance.

Industry Context

This filing is a routine disclosure of stock transactions by a company executive, which is a common practice for publicly traded companies. It provides transparency into the trading activities of insiders.

Comparison to Industry Standards

• Form 4 filings are standard practice for publicly traded companies in the US, ensuring transparency of insider trading activities.
• Comparable companies like Danaher, Thermo Fisher Scientific, and Agilent Technologies also have executives who regularly file Form 4s to report similar transactions.

Stakeholder Impact

• The transactions may have a minor impact on shareholders due to the change in ownership, but the overall effect is likely minimal.

Key Dates